Volume 11 Supplement 1

Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection

Open Access

Health-related quality of life in HIV-infected patients in a private practice in Germany

  • S Mauss1,
  • J Henke1,
  • F Berger1,
  • P Hegener1 and
  • G Schmutz1
Journal of the International AIDS Society200811(Suppl 1):P160

DOI: 10.1186/1758-2652-11-S1-P160

Published: 10 November 2008

Background

With improved treatment options, HIV infection has become a well treatable disease. Nevertheless, chronic disease and toxicities of long-term therapy may impair quality of life (QoL).

Methods

Cross-sectional study (n = 209) using a self-administered 28-item-questionnaire (six scales measuring quality of life, SEL) validated for HIV patients. For statistical analysis non-parametric tests were used. Antiretrovirals used (>10 patients) were: lamivudine/emtricitabine 152, tenofovir 121, abacavir 32, zidovudine 30; NNRTIs: efavirenz 50, nevirapine 28; PIs: lopinavir 31, atazanavir 17, saquinavir 12, darunavir 11.

Summary of results

Mean age 44 years; 89% male. CDC stage (1998) was A 44%, B 32% and C 24%. 80% received ART.

No difference in overall QoL between treated (3.62 ± 0.79) and untreated patients (3.66 ± 0.80) (p = 0.78) was observed. All patients rated their physical state better (QoL-P) (3.73 ± 0.85) than their cognitive-emotional (QoL-CE) (3.44 ± 0.86) (p < 0.001), regardless of being treated or not. There was no correlation between CD4+-cells and any QoL-domain. Patients in stage CDC A had a better QoL in all domains compared to patients with a history of symptomatic infection CDC B or CDC C (p < 0.05).

Patients on NNRTIs reported a better QoL than patients on PIs for QoL-P (3.91 ± 0.79 vs. 3.58 ± 0.87), QoL-CE (3.65 ± 0.83 vs. 3.31 ± 0.89) and overall QoL (3.80 ± 0.81 vs. 3.48 ± 0.84) (all p < 0.05). However, a higher proportion of patients with advanced HIV infection were treated with PIs compared to NNRTIs: CDC A 34%/61%, CDC B 59%/42%, and CDC C 56%/40% (p < 0.05).

Overall, QoL-score was lower in HIV+ patients (3.63 ± 0.79) than in the healthy reference sample (3.81 ± 0.53) but better than the historic HIV+ sample (3.51 ± 0.62) from mid-1990s. Improved QoL of HIV+ patients with and without current antiretroviral therapy compared to patients from mid-1990s was observed in all QoL domains.

Conclusion

HIV+ patients rate their QoL worse than healthy controls but better than HIV+ individuals from mid-1990s. Compared to HIV-negative individuals, QoL is impaired in the cognitive-emotional domain independent of health status. This suggests that being HIV-infected represents an emotional stress despite improved physical well-being. Effects of different drug classes should be interpreted carefully due to a potential selection bias.

Authors’ Affiliations

(1)
Center for HIV and Hepatogastroenterology

Copyright

© Mauss et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement